Form 8-K Edgewise Therapeutics, For: Aug 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Raymond James Reiterates Strong Buy Rating on Edgewise Therapeutics (EWTX)
August 7, 2025 10:44 AM EDTRaymond James analyst Martin Auster reiterated a Strong Buy rating and $46.00 price target on Edgewise Therapeutics (NASDAQ: EWTX).
The analyst comments "EWTX reported 2Q financial results and provided a corporate update. Timing for key catalysts remains on track. We continue to believe that EWTX offers among the most attractive risk/reward skews in our coverage universe into CIRRUS-HCM Part D results (beginning in 4Q25); we reiterate our Strong Buy rating. Update from EDG-7500 Phase 2 CIRRUS-HCM Part D (12-week) expected in 4Q25. EWTX previously reported 4-week Phase 2 CIRRUS-HCM (Parts B/C) data in... More
